<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72654">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159859</url>
  </required_header>
  <id_info>
    <org_study_id>OH-D-Ertapenem-HD</org_study_id>
    <nct_id>NCT02159859</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients</brief_title>
  <official_title>Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oakwood Hospital and Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oakwood Hospital and Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the amount of ertapenem in the blood over time
      between hemodialysis session.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a hemodialysis session, subject will be administered ertapenem and the amount of
      ertapenem in the blood will be measured at seven time periods before the initiation of the
      next hemodialysis session.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximum concentration (Cmax) of ertapenem in hemodialysis patients</measure>
    <time_frame>once after hemodialysis session prior to ertapenem administration and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</time_frame>
    <description>Mean Cmax will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean minimum concentration (Cmin) of ertapenem in hemodialysis patients</measure>
    <time_frame>once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</time_frame>
    <description>Mean Cmin will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of ertapenem in hemodialysis patients</measure>
    <time_frame>once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</time_frame>
    <description>Mean AUC will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean terminal elimination rate constant (ke) of ertapenem in hemodialysis patients</measure>
    <time_frame>once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</time_frame>
    <description>Mean ke will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean terminal half life (t1/2) of ertpenem in hemodialysis patients</measure>
    <time_frame>once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</time_frame>
    <description>Mean t1/2 will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time to Cmax of ertapenem in hemodialysis patients</measure>
    <time_frame>once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</time_frame>
    <description>Mean time to Cmax will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with diarrhea</measure>
    <time_frame>Up to seven days after the administration of ertapenem</time_frame>
    <description>Evaluation of diarrhea will be performed by the study physician at screening, predose, 24 hours, and 5 to 7 days after the ertapenem dose or the last day of patient's stay in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with nausea and vomiting</measure>
    <time_frame>Up to seven days after the administration of ertapenem</time_frame>
    <description>Evaluation of nausea and vomiting will be performed by the study physician at screening, predose, 24 hours, and 5 to 7 days after the ertapenem dose or the last day of patient's stay in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with headache</measure>
    <time_frame>Up to seven days after the administration of ertapenem</time_frame>
    <description>Evaluation of headache will be performed by the study physician at screening, predose, 24 hours, and 5 to 7 days after the ertapenem dose or the last day of patient's stay in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with injection site reaction</measure>
    <time_frame>Up to seven days after the administration of ertapenem</time_frame>
    <description>Evaluation of injection site reaction will be performed by the study physician at screening, predose, 24 hours, and 5 to 7 days after the ertapenem dose or the last day of patient's stay in the hospital</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with any adverse events</measure>
    <time_frame>Up to seven days after the administration of ertapenem</time_frame>
    <description>Evaluation of any adverse events will be performed by the study physician at screening, predose, 24 hours, and 5 to 7 days after the ertapenem dose or the last day of patient's stay in the hospital</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Invanz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age between 18 and 88 at the time of admission to Oakwood Hospital and
             Medical Center during January 1, 2014 or date of Institutional Review Board (IRB)
             approval to December 1, 2015

          -  Diagnosed with end stage renal disease and requires hemodialysis three times a week

          -  No allergy to Î² lactam medications

          -  Existing IV access for parenteral ertapenem infusion

          -  Willing for blood draws, at predose, 0.5, 1, 2, 6, 12 hours post-hemodialysis and
             pre-hemodialysis for the following hemodialysis

          -  No evidence of hepatic disease

          -  No history of alcoholism or drug abuse within pervious 2 years

          -  Not pregnant

        Exclusion Criteria:

          -  History of any form of epilepsy, seizure or convulsion

          -  Currently taking any forms of valproic acid or divalproex sodium for treatment of any
             disease states

          -  Currently taking probenecid

          -  Current Clostridium difficile (C. diff.) infection, defined as 30 days prior to day-1
             of receiving ertapenem for this study

          -  Currently receiving any antimicrobial agents for prophylaxis or treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Cha, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oakwood Hospital and Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sin-Ling T Jennings, Pharm.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Oakwood Hospital and Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond Cha, Pharm.D.</last_name>
    <phone>313-982-5496</phone>
    <email>raymond.cha@oakwood.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sin-Ling T Jennings, Pharm.D.</last_name>
    <phone>313-593-8759</phone>
    <email>sin-ling.jennings@oakwood.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oakwood Hospital and Medical Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raymond Cha, Pharm.D.</last_name>
      <phone>313-982-5496</phone>
      <email>raymond.cha@oakwood.org</email>
    </contact>
    <contact_backup>
      <last_name>Sin-Ling T Jennings, Pharm.D.</last_name>
      <phone>313-593-8759</phone>
      <email>sin-ling.jennings@oakwood.org</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond Cha, Pharm.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sin-Ling T Jennings, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lama Hsaiky, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francine Salinitri, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rabih Bazzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Britt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 7, 2014</lastchanged_date>
  <firstreceived_date>June 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oakwood Hospital and Medical Center</investigator_affiliation>
    <investigator_full_name>Raymond Cha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ertapenem</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>requires hemodialysis three times a week</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
